Several studies demonstrated that CD44 is a potential therapeutic target among various malignant entities, e.g., triple-negative basal-like breast cancer, squamous cell carcinomas, and acute myelogenous leukemia (Yan et al., 2015; Xu et al., 2020; Elakad et al., 2022). Here, CD44 is linked to squamous cell carcinoma.